These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 18444791

  • 1. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
    Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR, Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.
    Clin Infect Dis; 2008 Jun 01; 46(11):1683-93. PubMed ID: 18444791
    [Abstract] [Full Text] [Related]

  • 2. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR, FAST Investigator Group.
    Clin Infect Dis; 2005 Jun 01; 40(11):1601-7. PubMed ID: 15889357
    [Abstract] [Full Text] [Related]

  • 3. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere SL, Kitt MM, Corey GR, FAST 2 Investigator Group.
    Antimicrob Agents Chemother; 2006 Mar 01; 50(3):862-7. PubMed ID: 16495243
    [Abstract] [Full Text] [Related]

  • 4. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
    Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM, ATLAS Investigators.
    Am J Surg; 2009 Jun 01; 197(6):791-6. PubMed ID: 19095213
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
    Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL.
    Pharmacotherapy; 2008 Dec 01; 28(12):1471-82. PubMed ID: 19025428
    [Abstract] [Full Text] [Related]

  • 6. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Linezolid Pediatric Study Group.
    Pediatr Infect Dis J; 2003 Aug 01; 22(8):677-86. PubMed ID: 12913766
    [Abstract] [Full Text] [Related]

  • 7. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH, Kish TD, Fung HB.
    Clin Ther; 2010 Dec 01; 32(13):2160-85. PubMed ID: 21316534
    [Abstract] [Full Text] [Related]

  • 8. Telavancin: a novel lipoglycopeptide.
    Saravolatz LD, Stein GE, Johnson LB.
    Clin Infect Dis; 2009 Dec 15; 49(12):1908-14. PubMed ID: 19911938
    [Abstract] [Full Text] [Related]

  • 9. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN, Rybak MJ.
    Pharmacotherapy; 2008 Apr 15; 28(4):458-68. PubMed ID: 18363530
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY, Calhoun JH, Thomas TS, Wirtz ED.
    J Antimicrob Chemother; 2009 Feb 15; 63(2):357-60. PubMed ID: 19060292
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H, 307 Study Group.
    J Antimicrob Chemother; 2008 Sep 15; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [Abstract] [Full Text] [Related]

  • 12. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
    Barriere SL.
    Future Microbiol; 2010 Dec 15; 5(12):1765-73. PubMed ID: 21080861
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W.
    Clin Infect Dis; 2005 Nov 15; 41(10):1407-15. PubMed ID: 16231250
    [Abstract] [Full Text] [Related]

  • 14. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.
    Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M.
    Pediatr Infect Dis J; 2003 Apr 15; 22(4):315-23. PubMed ID: 12690270
    [Abstract] [Full Text] [Related]

  • 15. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, Rybak MJ.
    Pharmacotherapy; 2007 Dec 15; 27(12):1611-8. PubMed ID: 18041881
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM, Barriere SL, Kitt MM, Benton BM.
    Diagn Microbiol Infect Dis; 2010 Oct 15; 68(2):181-5. PubMed ID: 20846593
    [Abstract] [Full Text] [Related]

  • 17. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
    Lin DF, Zhang YY, Wu JF, Wang F, Zheng JC, Miao JZ, Zheng LY, Sheng RY, Zhou X, Shen HH, Ijzerman MM, Croos-Dabrera RV, Sheng W.
    Int J Antimicrob Agents; 2008 Sep 15; 32(3):241-9. PubMed ID: 18635341
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G.
    Int J Infect Dis; 2005 Sep 15; 9(5):251-61. PubMed ID: 16099700
    [Abstract] [Full Text] [Related]

  • 19. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
    Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C.
    Clin Infect Dis; 2009 Jan 15; 48(2):203-12. PubMed ID: 19072714
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS.
    Clin Infect Dis; 2008 Mar 01; 46(5):647-55. PubMed ID: 18225981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.